The Cost-effectiveness, Health Benefits, and Financial Costs of New Antiviral Treatments for Hepatitis C Virus

Clinical Infectious Diseases

Volumn 61, Issue 2, 2015, Pages 157-168

  Rein, David B ^a   Wittenborn, John S ^a   Smith, Bryce D ^b   Liffmann, Danielle K ^a   Ward, John W ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

antiviral treatment; cost effectivenes; hepatitis C; pharmacoeconomics; public health

Indexed keywords

DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; LEDIPASVIR PLUS SOFOSBUVIR; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; SOFOSBUVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; SIMEPREVIR; URIDINE PHOSPHATE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; COST EFFECTIVENESS ANALYSIS; DEATH; FEMALE; FOLLOW UP; HEALTH CARE COST; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; LIFESPAN; MALE; NONHUMAN; POPULATION RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; TREATMENT RESPONSE; AGED; COMBINATION DRUG THERAPY; COST BENEFIT ANALYSIS; ECONOMICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MARKOV CHAIN; MIDDLE AGED; MORTALITY; STATISTICS AND NUMERICAL DATA; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MARKOV CHAINS; MIDDLE AGED; POLYETHYLENE GLYCOLS; QUALITY-ADJUSTED LIFE YEARS; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; UNITED STATES; URIDINE MONOPHOSPHATE; YOUNG ADULT;

EID: 84936751862     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ220     Document Type: Article

References (77)

1. CDC Division of Viral Hepatitis. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012; 61(RR-4):1-32.
2. Rein DB, Smith BD, Wittenborn JS, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med 2012; 156:263-70.
3. Moyer VA. Screening for hepatitis C virus infection in adults: US Preventive services task force recommendation statement. Ann Intern Med 2013; 159:349-57.
4. Liu S, Cipriano LE, Holodniy M, Goldhaber-Fiebert JD. Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States. PloS One 2013; 8:e58975.
5. Zeng W, Yankey D, Ganesh N, Pineau V, Smith PJ. Using soft refusal status in the cell-phone nonresponse adjustment in the National Immunization Survey. In: American Statistical Association. Joint Statistical Conference, 2012.
6. McGarry LJ, Pawar VS, Panchmatia HR, et al. Economic model of a birth cohort screening program for hepatitis C virus. Hepatology 2012; 55:1344-55.
7. Coffin PO, Scott JD, Golden MR, Sullivan SD. Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis 2012; 54:1259-71.
8. Eckman MH, Talal AH, Gordon SC, Schiff E, Sherman KE. Costeffectiveness of screening for chronic hepatitis C infection in the United States. Clin Infect Dis 2013; 56:1382-93.
9. McEwan P, Ward T, Yuan Y, Kim R, L'Italien G. The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States. Hepatology 2013; 58:54-64.
10. AASLD, IDSA. Recommendations for testing, managing, and treating hepatitis C. Available at: http://www.hcvguidelines.org/full-report/hcvtesting-and-linkage-care. Accessed 20 March 2014.
11. Yang D, Liang HJ, Li D, Wei X, Ma L, Jia Z. The efficacy and safety of telaprevir-based regimens for treating chronic hepatitis C virus genotype 1 infection: ameta-analysis of randomized trials. InternMed 2013; 52:653-60.
12. Consumer Reports. Best buy drugs, the pegylated interferons: treating hepatitis C, comparing effectiveness, safety, and price. Available at: http://www.consumerreports.org/health/resources/pdf/best-buy-drugs/ BBD-Hepatitis-C.pdf. Accessed 25 March.
13. Wright M, Grieve R, Roberts J, Main J, Thomas HC. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess 2006; 10:1-113, iii.
14. Adeyemi OM, Jensen D, Attar B, et al. Hepatitis C treatment eligibility in an urban population with and without HIV coinfection. AIDS Patient Care STDs 2004; 18:239-45.
15. Alfandre D, Gardenier D, Federman A, McGinn T. Hepatitis C in an urban cohort: who's not being treated? J Health Care Poor Underserved 2009; 20:1068-78.
16. Cheung RC, Cunningham BA, Cooper AD. Effectiveness of a screening program for hepatitis C. Dig Dis Sci 2006; 51:976-81.
17. Delwaide J, El Saouda R, Gerard C, Belaiche J; Groupe Liegeois d'Etude des Virus H. Hepatitis C infection: eligibility for antiviral therapies. Eur J Gastroenterol Hepatol 2005; 17:1185-9.
18. Evon DM, Verma A, Dougherty KA, et al. High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities. Dig Dis Sci 2007; 52:3251-8.
19. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002; 136:288-92.
20. Moirand R, Bilodeau M, Brissette S, Bruneau J. Determinants of antiviral treatment initiation in a hepatitis C-infected population benefiting from universal health care coverage. Can J Gastroenterol 2007; 21:355-61.
21. Morrill JA, Shrestha M, Grant RW. Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med 2005; 20:754-8.
22. Narasimhan G, Sargios TN, Kalakuntla R, et al. Treatment rates in patients with chronic hepatitis C after liver biopsy. J Viral Hepat 2006; 13:783-6.
23. Rifai MA, Moles JK, Lehman LP, Van der Linden BJ. Hepatitis C screening and treatment outcomes in patients with substance use/ dependence disorders. Psychosomatics 2006; 47:112-21.
24. Rowan PJ, Tabasi S, Abdul-Latif M, Kunik ME, El-Serag HB. Psychosocial factors are the most common contraindications for antiviral therapy at initial evaluation in veterans with chronic hepatitis C. J Clin Gastroenterol 2004; 38:530-4.
25. Rocca LG, Yawn BP, Wollan P, Kim WR. Management of patients with hepatitis C in a community population: diagnosis, discussions, and decisions to treat. Ann Fam Med 2004; 2:116-24.
26. AIDSMEDS. Fair Pricing Coalition says Vertex's Incivek price 'outrageous'. Available at: http://www.aidsmeds.com/articles/incivek-price- advocacy-1667-20508.shtml. Accessed 25 March 2015.
27. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368:1878-87.
28. Gilead. U.S. Food and Drug Administration approves Gilead's Sovaldi (Sofosbuvir) for the treatment of chronic Hepatitis C. Available at: http://www.gilead.com/news/press-releases/2013/12/us-food-and-drugadministration-approves-gileads-sovaldi-sofosbuvir-for-the-treatmentof-chronic-hepatitis-c. Accessed 25 March 2015.
29. Jacobson IM, Ghalib RH, Rodriguez-Torres M, et al. Abstract #LB-3: SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and noncirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: The COSMOS study. In: AASLD. Washington, DC, 2013.
30. Hepatitis C New Drug Research And Liver Health. OLYSIO Simeprevir Cost? Available at: http://hepatitiscnewdrugresearch.com/-olysiotradesimeprevir-cost.html. Accessed 25 March 2015.
31. Zeuzem S, Dusheiko GM, Salupere R, et al. Abstract# 1085: Sofosbuvir + Ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial. In: AASLD. Washington, DC, 2013.
32. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127:855-65.
33. Solomon L, Flynn C, Muck K, Vertefeuille J. Prevalence of HIV, syphilis, hepatitis B, and hepatitis C among entrants to Maryland correctional facilities. J Urban Health 2004; 81:25-37.
34. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013; 158(5 Pt 1):329-37.
35. Hagan H, Campbell J, Thiede H, et al. Self-reported hepatitis C virus antibody status and risk behavior in young injectors. Public Health Rep 2006; 121:710-9.
36. Wasley A, Finelli L, Bell B, Alter M. The knowledge and behaviors of HCV-infected persons identified in a seroprevalence survey, USA, 2001-2002. J Clin Virol 2006; 36(suppl 2):S198-9.
37. Honeycutt AA, Harris JL, Khavjou O, Buffington J, Jones TS, Rein DB. The costs and impacts of testing for hepatitis C virus antibodies in public STD clinics. Public Health Rep 2007; 122(suppl 2):55-62.
38. Chou R, Cottrell EB, Wasson N, Rahman B, Guise JM. Screening for hepatitis C virus infection in adults: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2013; 158:101-8.
39. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Empirically calibrated model of hepatitis C virus infection in the United States. Am J Epidemiol 2002; 156:761-73.
40. Culver DH, Alter MJ, Mullan RJ, Margolis HS. Evaluation of the effectiveness of targeted lookback for HCV infection in the United States- interim results. Transfusion 2000; 40:1176-81.
41. Planas R, Balleste B, Alvarez MA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol 2004; 40:823-30.
42. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112:463-72.
43. Ortner NJ, Cosway RG. US organ and tissue transplant cost estimates and discussion. Seattle: Milliman Consultants and Actuaries, 2005.
44. Jain A, Reyes J, Kashyap R, et al. Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg 2000; 232:490-500.
45. Vlahov D, Wang C, Ompad D, et al. Mortality risk among recent-onset injection drug users in five U.S. cities. Subst UseMisuse 2008; 43:413-28.
46. Centers for Medicare & Medicaid Services (CMS), 2014. Clinical Laboratory Fee Schedule. Available at: http://www.cms.gov/apps/ama/ license.aspfile=/ClinicalLabFeeSched/downloads/14CLAB.zip. Accessed 6 May 2014.
47. American Association for the Study of Liver Diseases: diagnosis, management, and treatment of Hepatitis C. Accessed 24 May 2007.
48. Carey WD, Fried MW, Jeffers L, et al. Hepatitis C management. In: The Cleveland Clinic, ed. The Cleveland clinic monograph series. Cleveland: The Cleveland Clinic Foundation, 2007.
49. Gray L, Parkinson J, eds. The essential RBRVS. Salt Lake City: St. Anthoney's Publishing, 2003.
50. Recommended adult immunization schedule-United States, October 2007-September 2008 (Reprinted from MMWR, vol 56, pg Q1-Q4, 2007). JAMA 2007; 298:2477-80.
51. Pediatric/VFC Vaccine Price List.
52. Rein DB, Wittenborn JS, Weinbaum CM, Sabin M, Smith BD, Lesesne SB. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis 2011; 43:66-72.
53. Chan K, Lai MN, Groessl EJ, et al. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the Veterans Health Administration. Clin Gastroenterol Hepatol 2013; 11:1503-10.
54. Milliman I. Liver transplant costs. In: Personal Communication RH, ed. Milwaukee, WI, 2007.
55. Englesbe MJ, Dimick J, Mathur A, et al. Who pays for biliary complications following liver transplant? A business case for quality improvement. Am J Transplant 2006; 6:2978-82.
56. Showstack J, Katz PP, Lake JR, et al. Resource utilization in liver transplantation: effects of patient characteristics and clinical practice. NIDDK Liver Transplantation Database Group. JAMA 1999; 281:1381-6.
57. Berge JJ, Drennan DP, Jacobs RJ, et al. The cost of hepatitis A infections in American adolescents and adults in 1997. Hepatology 2000; 31: 469-73.
58. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90:1562-9.
59. (CDC) CfDCaP. National Center for Health Statistics (NCHS), National Health and Nutrition Examination Survey (NHANES) Data. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 1999-2010.
60. Centers for Disease Control and Prevention. National Center for Health Statistics. National Health and Nutrition Examination Survey Data. Vol. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2001-2006. Available at: http:// www.cdc.gov/nchs/about/major/nhanes/datalink.htm. Accessed 28 April 15.
61. Nainan OV, Alter MJ, Kruszon-Moran D, et al. Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastroenterology 2006; 131: 478-84.
62. US Census. PEPASR5H. Annual estimates of the resident population by sex, age, race alone or in combination, and Hispanic origin for the United States and States: April 1, 2010 to July 1, 2012.
63. Centers for Disease Control and Prevention. National Center for Health Statistics. National Health and Nutrition Examination Survey Data. Vol. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 1999-2010. Available at: http:// www.cdc.gov/nchs/about/major/nhanes/datalink.htm. Accessed 28 April 15.
64. Chou R, Cottrell EB, Wasson N, Rahman B, Guise JM. Screening for hepatitis C virus infection in adults: a systematic review to update the 2004 U.S. preventive services task force recommendation. Ann Intern Med 2012; 158:101-8.
65. Kwiatkowski CF, Fortuin Corsi K, Booth RE. The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users. Addiction 2002; 97:1289-94.
66. Smith BD, Yartel AK, Krauskopf K, et al. Hepatitis C virus (HCV) antibody positivity and predictors among previously undiagnosed adult primary care outpatients: cross-sectional analysis of a multi-site retrospective cohort study. Clin Infect Dis 2015; 60:1145-52.
67. Arias E. United States life tables, 2003. Natl Vital Stat Rep 2006; 54:1-40.
68. Chen F. Paper 257-2009: Bayesian modeling using the MCMCprocedure. Available at: http://support.sas.com/resources/papers/proceedings09/257-2009.pdf. Accessed 17 April 2014.
69. Gold MR, Franks P, McCoy KI, Fryback DG. Toward consistency in cost-utility analyses: using national measures to create conditionspecific values. Medical Care 1998; 36:778-92.
70. Chong CA, Gulamhussein A, Heathcote EJ, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003; 98:630-8.
71. Siebert U, Sroczynski G. Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security. Int J Technol Assess Health Care 2005; 21:55-65.
72. Sherman KE, Sherman SN, Chenier T, Tsevat J. Health values of patients with chronic hepatitis C infection. Arch Intern Med 2004; 164:2377-82.
73. Thein HH, Krahn M, Kaldor JM, Dore GJ. Estimation of utilities for chronic hepatitis C from SF-36 scores. Am J Gastroenterol 2005; 100:643-51.
74. Grieve R, Roberts J, Wright M, et al. Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut 2006; 55:1332-8.
75. Yehia BR, Schranz AJ, Umscheid CA, Lo Re V, III. The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PloS one 2014; 9:e101554.
76. Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med 2013; 368:1859-61.
77. Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infecti Dis 2013; 57(suppl 2):S39-45.